Education
About Us
Working with TipRanks
Follow Us
Dr. Hoenle AG (DE:HNL)
XETRA:HNL
HNL Stock Chart & Stats
€7.10
-€0.20(-2.86%)
At close: 4:00 PM EST
€7.10
-€0.20(-2.86%)
Day’s Range― - ―
52-Week Range€6.48 - €11.90
Previous CloseN/A
Volume3.05K
Average Volume (3M)6.13K
Market Cap
€52.74M
Enterprise Value€94.35M
Total Cash (Recent Filing)€7.75M
Total Debt (Recent Filing)€49.25M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Feb 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding6,062,930
10 Day Avg. Volume3,193
30 Day Avg. Volume6,130
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Aftermarket RevenueDr. Hönle’s business model includes sales of consumable UV lamps, quartz components, measurement instruments and service tied to installed systems. That recurring aftermarket demand creates stable, repeatable cash flows and margin support over the medium term, cushioning capex cyclicality.
Improving Cash GenerationOperating and free cash flow turning positive across 2023–2025 indicates the company is converting operations into real cash. Sustained FCF enables reinvestment, supports working capital needs and reduces reliance on external financing, improving financial flexibility over the coming months.
Manageable Leverage And Declining DebtA moderate debt profile and declining total debt since 2023 preserve the company’s ability to fund operations and investments without excessive interest burden. This structural improvement in leverage enhances resilience to cyclical downturns and supports strategic execution over a 2–6 month horizon.
Bears Say
Multi-year Revenue DeclineA sustained revenue downtrend erodes scale economies and weakens pricing leverage. If top-line contraction persists, it pressures gross margins, reduces R&D and sales investment capacity, and limits the company’s ability to restore profitable growth over the medium term.
Persistent Net Losses And Weak MarginsRecurring net losses and negative margins imply the business has struggled to convert sales into sustainable profits. Continued operating losses risk equity erosion, constrain capital allocation choices, and make long-term returns to shareholders contingent on durable margin recovery.
Historical Cash-flow VolatilityDespite recent positive cash flow, prior years of negative operating and free cash flow indicate underlying volatility. Such swings can disrupt investment plans, force precautionary financing or cost cuts, and make consistent execution and planning harder over the next several quarters.
Dr. Hoenle AG News
HNL FAQ
What was Dr. Hoenle AG’s price range in the past 12 months?
Dr. Hoenle AG lowest stock price was €6.48 and its highest was €11.90 in the past 12 months.
What is Dr. Hoenle AG’s market cap?
Dr. Hoenle AG’s market cap is €52.74M.
When is Dr. Hoenle AG’s upcoming earnings report date?
Dr. Hoenle AG’s upcoming earnings report date is Feb 24, 2026 which is tomorrow.
How were Dr. Hoenle AG’s earnings last quarter?
Dr. Hoenle AG released its earnings results on Dec 08, 2025. The company reported -€0.31 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.31.
Is Dr. Hoenle AG overvalued?
According to Wall Street analysts Dr. Hoenle AG’s price is currently Overvalued.
Does Dr. Hoenle AG pay dividends?
Dr. Hoenle AG pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Dr. Hoenle AG dividends here
What is Dr. Hoenle AG’s EPS estimate?
Dr. Hoenle AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dr. Hoenle AG have?
Dr. Hoenle AG has 6,062,930 shares outstanding.
What happened to Dr. Hoenle AG’s price movement after its last earnings report?
Dr. Hoenle AG reported an EPS of -€0.31 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.449%.
Which hedge fund is a major shareholder of Dr. Hoenle AG?
Currently, no hedge funds are holding shares in DE:HNL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Hoenle AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.44%
12-Months-Change
Fundamentals
Return on Equity
-15.84%
Trailing 12-Months
Asset Growth
-11.57%
Trailing 12-Months
Company Description
Dr. Hoenle AG
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.
Technical Analysis
Options Prices
Currently, No data available
---